Big Pharma companies have paid some big fines in recent years for compliance failures for failing to mitigate bribery and corruption risk effectively, including one FCPA enforcement action that resulted in $519 million in fines and remediation. How do you ensure your due diligence process isn’t just a placebo?

Coping with rising risk & record fines

Our Pharma in Focus whitepaper, “How a healthy risk mitigation process can prevent catastrophic failure,” takes a closer look at the complexities of managing risk across various facets of the Pharma industry—from identifying red flags in M&A deals to ensuring that subsidiaries or other third-party agents acting on your behalf stay on the right side of applicable laws. Get insights into:

• What kinds of compliance failures are behind the largest Pharma fines?
• How is the issue of ethics influencing the Pharma risk landscape?
• What do regulators expect to see in a risk management process?

The risks Pharma organizations face keep changing. Has your risk management process kept pace with change?

Implement an agile due diligence process

Understanding the risk landscape and adapting your due diligence process as it evolves plays a crucial role in effectively mitigating risk. Globalization, for example, has led to demand in new markets. Unfortunately, emerging markets may increase exposure to bribery and corruption risk. In some countries, for instance, doctors may qualify as Politically Exposed Persons because they operate in state-owned healthcare facilities. This increases FCPA risk, so Pharma companies must approach sales incentives with caution.

Download the whitepaper including a useful 10-step Pharma risk management checklist.